{"id":545,"date":"2022-07-27T06:31:08","date_gmt":"2022-07-27T06:31:08","guid":{"rendered":"https:\/\/truximainfo.ca\/?page_id=545"},"modified":"2026-09-18T05:17:59","modified_gmt":"2026-09-18T05:17:59","slug":"accueil","status":"publish","type":"page","link":"https:\/\/truximainfo.ca\/fr\/","title":{"rendered":"Accueil"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"545\" class=\"elementor elementor-545\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ec6f1e0 elementor-section-stretched elementor-section-full_width elementor-section-height-default elementor-section-height-default\" data-id=\"ec6f1e0\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-94a8f76\" data-id=\"94a8f76\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-73e1a61\" data-id=\"73e1a61\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-abec177 elementor-widget elementor-widget-heading\" data-id=\"abec177\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Acc\u00e9dez aux plus r\u00e9centes ressources sur <sup>Pr<\/sup>TRUXIMA<sup>MD<\/sup> et <br>le programme de soutien aux patients Teva Support Solutions<sup>MD<\/sup><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-a6f5545 elementor-section-full_width elementor-section-content-middle elementor-section-height-default elementor-section-height-default\" data-id=\"a6f5545\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-e05a0bf\" data-id=\"e05a0bf\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e737342 heading-border elementor-widget elementor-widget-heading\" data-id=\"e737342\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Biosimilaires de conception.<br>Biologique par essence.\n\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-f7916d6\" data-id=\"f7916d6\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-fb2eb68 elementor-widget elementor-widget-image\" data-id=\"fb2eb68\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1000\" height=\"438\" src=\"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR.png\" class=\"attachment-full size-full wp-image-1207\" alt=\"\" srcset=\"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR.png 1000w, https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR-300x131.png 300w, https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR-768x336.png 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-bbf7ad7 elementor-section-stretched elementor-section-full_width elementor-section-height-default elementor-section-height-default\" data-id=\"bbf7ad7\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-b7de21a\" data-id=\"b7de21a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-209dc68 elementor-widget elementor-widget-heading\" data-id=\"209dc68\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">TRUXIMA<sup>MD<\/sup> en oncologie<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fde302f small-para-cls elementor-widget elementor-widget-heading\" data-id=\"fde302f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Lymphome non hodgkinien (LNH)<sup>1<\/sup>*<sup>\u2020<\/sup><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7e309e0 elementor-widget elementor-widget-text-editor\" data-id=\"7e309e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tTRUXIMA<sup>MD<\/sup> (rituximab pour injection) est indiqu\u00e9 dans le traitement des patients atteints d\u2019un lymphome non hodgkinien de type B, CD20 positif, folliculaire, de stade III\/IV non trait\u00e9 auparavant, en association avec un protocole de chimioth\u00e9rapie CVP (cyclophosphamide, vincristine et prednisolone).\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a2dec4b small-para-cls elementor-widget elementor-widget-heading\" data-id=\"a2dec4b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Leuc\u00e9mie lympho\u00efde chronique (LLC)<sup>1\u2020<\/sup><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-af7c2f3 elementor-widget elementor-widget-text-editor\" data-id=\"af7c2f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tTRUXIMA<sup>MD<\/sup> (rituximab pour injection) est indiqu\u00e9 dans le traitement des patients atteints de leuc\u00e9mie lympho\u00efde chronique \u00e0 cellules B (LLC-B) de stade B ou C de Binet, ayant \u00e9t\u00e9 trait\u00e9s auparavant ou n\u2019ayant jamais \u00e9t\u00e9 trait\u00e9s, en association avec la fludarabine et le cyclophosphamide.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-262cc05\" data-id=\"262cc05\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-fda8150 elementor-widget elementor-widget-heading\" data-id=\"fda8150\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">TRUXIMA<sup>MD<\/sup> en rhumatologie<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-a0d343f elementor-section-full_width elementor-section-height-default elementor-section-height-default\" data-id=\"a0d343f\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-c1e2d2e\" data-id=\"c1e2d2e\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f2cbad4 elementor-widget elementor-widget-image\" data-id=\"f2cbad4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"161\" height=\"161\" src=\"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/08\/PR-Logo.png\" class=\"attachment-full size-full wp-image-2786\" alt=\"\" srcset=\"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/08\/PR-Logo.png 161w, https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/08\/PR-Logo-150x150.png 150w\" sizes=\"(max-width: 161px) 100vw, 161px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-f89da73\" data-id=\"f89da73\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-9bccfbf small-para-cls elementor-widget elementor-widget-heading\" data-id=\"9bccfbf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Polyarthrite rhumato\u00efde (PR)<sup>1\u2020<\/sup><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4b03492 elementor-widget elementor-widget-text-editor\" data-id=\"4b03492\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tTRUXIMA<sup>MD<\/sup>, en association avec le m\u00e9thotrexate, est indiqu\u00e9 pour soulager les signes et les sympt\u00f4mes de la PR \u00e9volutive mod\u00e9r\u00e9e ou grave chez les adultes ayant montr\u00e9 une r\u00e9ponse inad\u00e9quate ou une intol\u00e9rance \u00e0 un ou plusieurs traitements par des inhibiteurs du facteur de n\u00e9crose tumorale (anti-TNF).\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-f071c39 elementor-section-full_width elementor-section-height-default elementor-section-height-default\" data-id=\"f071c39\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-86c9df6\" data-id=\"86c9df6\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4b21027 elementor-widget elementor-widget-image\" data-id=\"4b21027\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"161\" height=\"280\" src=\"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/08\/GPA-PAM-logo.png\" class=\"attachment-full size-full wp-image-2784\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-567a9b3\" data-id=\"567a9b3\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-42e43cb small-para-cls elementor-widget elementor-widget-heading\" data-id=\"42e43cb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Vasculite \u00e0 ANCA<sup>1,2\u2020<\/sup><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-05de942 elementor-widget elementor-widget-text-editor\" data-id=\"05de942\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tTRUXIMA<sup>MD<\/sup>, en association avec des glucocortico\u00efdes, est indiqu\u00e9 chez les adultes comme traitement d\u2019induction de la r\u00e9mission de la granulomatose avec polyang\u00e9ite (GPA, aussi connue sous le nom de granulomatose de Wegener) et de la polyang\u00e9ite microscopique (PAM) actives et graves.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a23bd81 elementor-section-full_width elementor-section-height-default elementor-section-height-default\" data-id=\"a23bd81\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-86a5fce\" data-id=\"86a5fce\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d31fc91 home-add-fontsize elementor-widget elementor-widget-heading\" data-id=\"d31fc91\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h6 class=\"elementor-heading-title elementor-size-default\">Renseignements relatifs \u00e0 l\u2019innocuit\u00e9 de TRUXIMA<sup>MD1<\/sup><\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-e66b23e elementor-section-full_width elementor-section-height-default elementor-section-height-default\" data-id=\"e66b23e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-e4a4f26\" data-id=\"e4a4f26\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c33fe8f home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"c33fe8f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div><span style=\"text-decoration: underline;\"><b class=\"home-add-fontsize\">Usage clinique<\/b><\/span> :<\/div>\nL\u2019emploi dans la LLC se base sur la prolongation de la survie sans progression. L\u2019effet b\u00e9n\u00e9fique relatif \u00e0 la survie globale n\u2019a pas \u00e9t\u00e9 d\u00e9montr\u00e9 chez les patients ayant \u00e9t\u00e9 trait\u00e9s auparavant. L\u2019efficacit\u00e9 en association avec la fludarabine et le cyclophosphamide n\u2019a pas \u00e9t\u00e9 \u00e9tudi\u00e9e chez les patients qui avaient d\u00e9j\u00e0 re\u00e7u cette association.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b8f6755 home-add-fontsize-para elementor-hidden-desktop elementor-hidden-laptop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"b8f6755\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>L\u2019analyse exploratoire de sous-groupes indique que l\u2019administration \u00e0 des personnes \u00e2g\u00e9es (\u2265 65 ans) est associ\u00e9e \u00e0 des diff\u00e9rences d\u2019efficacit\u00e9 et d\u2019innocuit\u00e9.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8b2061c home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"8b2061c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tIl a \u00e9t\u00e9 d\u00e9montr\u00e9 par radiographie que TRUXIMA<sup>MD<\/sup>, en association avec le m\u00e9thotrexate, ralentit la progression des l\u00e9sions articulaires. Il faut tenir compte des directives th\u00e9rapeutiques actuelles au sujet des vasculites.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fd1b648 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"fd1b648\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<strong>P\u00e9diatrie (< 18 ans) :<\/strong> L\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 de TRUXIMA<sup>MD<\/sup> n\u2019ont pas \u00e9t\u00e9 \u00e9tablies chez les enfants. Par cons\u00e9quent, Sant\u00e9 Canada n\u2019a pas autoris\u00e9 d\u2019indication pour cette population.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dbb46be home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"dbb46be\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<strong>G\u00e9riatrie (\u2265 65 ans) :<\/strong> Dans les cas de LLC, l\u2019analyse exploratoire de sous-groupes indique que l\u2019administration \u00e0 des personnes \u00e2g\u00e9es est associ\u00e9e \u00e0 des diff\u00e9rences d\u2019efficacit\u00e9 et d\u2019innocuit\u00e9. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8cdac9a home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"8cdac9a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div><span style=\"text-decoration: underline;\"><b class=\"home-add-fontsize\">Contre-indications<\/b><\/span> :<\/div>\nCas connus d\u2019hypersensibilit\u00e9 de type I ou de r\u00e9actions anaphylactiques aux prot\u00e9ines murines, aux prot\u00e9ines de cellules ovariennes de hamster chinois ou \u00e0 tout constituant du produit.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-148ad72 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"148ad72\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tPatients qui sont atteints de leucoenc\u00e9phalopathie multifocale progressive (LEMP) ou qui en ont \u00e9t\u00e9 atteints auparavant.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8b1747c home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"8b1747c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tL\u2019emploi de TRUXIMA<sup>MD<\/sup> n\u2019est pas recommand\u00e9 en pr\u00e9sence d\u2019infection grave et \u00e9volutive.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3b3c002 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"3b3c002\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div><span style=\"text-decoration: underline;\"><b class=\"home-add-fontsize\">Mises en garde et pr\u00e9cautions les plus importantes<\/b><\/span> :<\/div>\n<div><b class=\"home-add-fontsize\">Risque de r\u00e9actions ind\u00e9sirables graves et mena\u00e7ant le pronostic vital :<\/b> L\u2019emploi de TRUXIMA<sup>MD<\/sup> est associ\u00e9 \u00e0 plusieurs r\u00e9actions ind\u00e9sirables, dont certaines sont graves et menacent le pronostic vital. Ce produit ne doit \u00eatre administr\u00e9 que par des professionnels de la sant\u00e9 exp\u00e9riment\u00e9s dans le traitement du LNH, de la LLC, de la PR, de la GPA (aussi connue sous le nom de granulomatose de Wegener) et de la PAM. Traiter dans un environnement o\u00f9 tous les appareils de r\u00e9animation sont imm\u00e9diatement accessibles, et o\u00f9 les m\u00e9dicaments et les soins de soutien n\u00e9cessaires au traitement des r\u00e9actions d\u2019hypersensibilit\u00e9 (par exemple \u00e9pin\u00e9phrine, antihistaminiques et glucocortico\u00efdes) sont imm\u00e9diatement accessibles advenant une r\u00e9action allergique durant la perfusion.<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fa07ead home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"fa07ead\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<b class=\"home-add-fontsize\">R\u00e9actions li\u00e9es \u00e0 la perfusion : <\/b>Des d\u00e9c\u00e8s sont survenus dans les 24 heures suivant la perfusion. Environ 80 % de ceux-ci \u00e9taient associ\u00e9s \u00e0 la premi\u00e8re perfusion. Surveiller attentivement les patients durant les perfusions. Arr\u00eater la perfusion et administrer un traitement m\u00e9dical en cas de r\u00e9actions \u00e0 la perfusion de grade 3 ou 4.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5136140 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"5136140\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<b class=\"home-add-fontsize\">Leucoenc\u00e9phalopathie multifocale progressive (LEMP) : <\/b>Les patients atteints de PR, de LNH ou de LLC peuvent courir un risque accru de LEMP, qui peut entra\u00eener une invalidit\u00e9 ou la mort. Les patients doivent faire l\u2019objet d\u2019une surveillance visant \u00e0 d\u00e9celer tout signe ou sympt\u00f4me \u00e9vocateur de LEMP. L\u2019arr\u00eat imm\u00e9diat du traitement par TRUXIMA<sup>MD<\/sup> s\u2019impose d\u00e8s l\u2019apparition du premier signe ou sympt\u00f4me \u00e9voquant la LEMP.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7647812 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"7647812\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<b class=\"home-add-fontsize\">Syndrome de lyse tumorale (SLT) : <\/b>Des cas d\u2019insuffisance r\u00e9nale aigu\u00eb n\u00e9cessitant une dialyse et se soldant par le d\u00e9c\u00e8s ont \u00e9t\u00e9 signal\u00e9s en lien avec un SLT apr\u00e8s le traitement d\u2019un LNH.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-d04ce9a\" data-id=\"d04ce9a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c11b457 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"c11b457\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<b class=\"home-add-fontsize\">R\u00e9activation du virus de l\u2019h\u00e9patite B (VHB) : <\/b>Une r\u00e9activation du VHB est survenue, entra\u00eenant dans certains cas une h\u00e9patite fulminante, une insuffisance h\u00e9patique, voire le d\u00e9c\u00e8s. Il faut soumettre tous les patients au d\u00e9pistage du VHB avant d\u2019instaurer le traitement et les surveiller pendant et apr\u00e8s le traitement. Advenant une r\u00e9activation du VHB, il y aurait lieu de cesser l\u2019administration de TRUXIMA<sup>MD<\/sup> et des m\u00e9dicaments concomitants.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6a34629 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"6a34629\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<b class=\"home-add-fontsize\">R\u00e9actions cutan\u00e9o-muqueuses : <\/b>De graves r\u00e9actions cutan\u00e9o-muqueuses, parfois mortelles, dont des cas d\u2019\u00e9rythrodermie bulleuse avec \u00e9pidermolyse et de syndrome de Stevens-Johnson, ont \u00e9t\u00e9 observ\u00e9es. Suspendre le traitement et consulter imm\u00e9diatement un m\u00e9decin. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-41e66ce home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"41e66ce\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<b class=\"home-add-fontsize\">Infections : <\/b> De graves infections, parfois mortelles, de nature bact\u00e9rienne ou fongique, ou des infections virales, qu\u2019elles soient nouvelles ou r\u00e9activ\u00e9es, peuvent survenir pendant le traitement ou apr\u00e8s la fin du traitement. Il ne faut pas amorcer un traitement chez les patients atteints d\u2019une infection \u00e9volutive grave. Il faut v\u00e9rifier les ant\u00e9c\u00e9dents de maladie infectieuse du patient.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f7351b9 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"f7351b9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<b class=\"home-add-fontsize\">Appareil cardiovasculaire : <\/b> Dans de rares cas, des manifestations cardiovasculaires graves et potentiellement mortelles ont \u00e9t\u00e9 signal\u00e9es.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8938464 home-add-fontsizeandline elementor-widget elementor-widget-heading\" data-id=\"8938464\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h6 class=\"elementor-heading-title elementor-size-default\"><u>Autres mises en garde et pr\u00e9cautions pertinentes <\/u> :<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-595ca2b home-add-fontsize-para elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"595ca2b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Doit \u00eatre administr\u00e9 par perfusion i.v. dans une tubulure r\u00e9serv\u00e9e \u00e0 ce m\u00e9dicament. Ne pas administrer par voie intraveineuse rapide ni sous forme de bolus intraveineux.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Les professionnels de la sant\u00e9 doivent consigner \u00e0 la fois le nom commercial et la d\u00e9nomination commune (ingr\u00e9dient actif) ainsi que d\u2019autres identificateurs propres au produit, comme le num\u00e9ro d\u2019identification du m\u00e9dicament (DIN) et le num\u00e9ro de lot du produit fourni.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Les personnes qui conduisent, font fonctionner un v\u00e9hicule ou utilisent des machines potentiellement dangereuses doivent prendre des mesures de pr\u00e9cautions appropri\u00e9es.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Manifestations pulmonaires incluant une hypoxie, une infiltration pulmonaire et une insuffisance respiratoire aigu\u00eb.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Chez les patients atteints de LNH ou de LLC, envisager la prophylaxie du SLT chez les patients susceptibles de pr\u00e9senter une lyse tumorale rapide (p. ex. les patients pr\u00e9sentant une forte charge tumorale ou un nombre \u00e9lev\u00e9 [&gt; 25 \u00d7 10<sup>9<\/sup>\/L] de cellules malignes circulantes, comme les patients atteints de LLC ou d\u2019un lymphome \u00e0 cellules du manteau).<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">R\u00e9actions anaphylactiques, y compris le d\u00e9c\u00e8s.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Les femmes fertiles doivent utiliser des m\u00e9thodes contraceptives efficaces pendant le traitement et jusqu\u2019\u00e0 12 mois apr\u00e8s la fin du traitement. <\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Une hypotension peut survenir pendant la perfusion de TRUXIMA<sup>MD<\/sup>. Envisager de suspendre l\u2019administration des m\u00e9dicaments antihypertenseurs pendant les 12 heures qui pr\u00e9c\u00e8dent la perfusion et jusqu\u2019\u00e0 ce qu\u2019elle soit termin\u00e9e.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">La plainte d\u2019une douleur abdominale, en particulier au d\u00e9but du traitement, devrait inciter \u00e0 effectuer une \u00e9valuation diagnostique approfondie afin d\u2019instaurer un traitement appropri\u00e9.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Bien que TRUXIMA<sup>MD<\/sup> ne soit pas un agent my\u00e9losuppresseur en monoth\u00e9rapie, il faut faire preuve de prudence lorsqu\u2019on envisage le traitement de patients chez qui le nombre de neutrophiles est inf\u00e9rieur \u00e0 1,5 \u00d7 10<sup>9<\/sup>\/L, et\/ou le nombre de plaquettes inf\u00e9rieur \u00e0 75 \u00d7 10<sup>9<\/sup>\/L, car l\u2019exp\u00e9rience clinique chez de tels patients est limit\u00e9e. La neutrop\u00e9nie de grade 3\u20134 et une baisse de la num\u00e9ration leucocytaire \u00e9taient tr\u00e8s courantes lorsque le rituximab pour injection \u00e9tait administr\u00e9 en association avec la fludarabine et le cyclophosphamide.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Rechercher attentivement tout signe d\u2019infection chez les patients atteints de PR qui re\u00e7oivent de fa\u00e7on concomitante un agent biologique et un antirhumatismal modificateur de la maladie (ARMM).<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-cd2c87f\" data-id=\"cd2c87f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ef3701d home-add-fontsize-para elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"ef3701d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Pr\u00e9sence d\u2019anticorps humain anti-souris (HAMA) et d\u2019anticorps humains anti-chim\u00e8res (HACA).<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">L\u2019immunisation par vaccins \u00e0 virus vivant n\u2019est pas recommand\u00e9e pendant le traitement ni au cours d\u2019une d\u00e9pl\u00e9tion en lymphocytes B p\u00e9riph\u00e9riques. La vaccination doit \u00eatre termin\u00e9e au moins 4 semaines avant la premi\u00e8re perfusion de TRUXIMA<sup>MD<\/sup>. Les patients trait\u00e9s peuvent recevoir des vaccins \u00e0 virus non vivant, mais le taux de r\u00e9ponse \u00e0 ces vaccins pourrait \u00eatre r\u00e9duit.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">D\u2019autres infections virales graves, qu\u2019elles soient nouvelles, r\u00e9activ\u00e9es ou exacerb\u00e9es, ont \u00e9t\u00e9 signal\u00e9es dans les \u00e9tudes cliniques ou les rapports de pharmacovigilance, dans la plupart des cas chez des patients qui pr\u00e9sentaient une immunod\u00e9pression marqu\u00e9e : virus de John Cunningham (JC), cytom\u00e9galovirus, virus de l\u2019herp\u00e8s simplex, parvovirus B19, virus varicelle-zona, virus du Nil occidental et virus de l\u2019h\u00e9patite C. L\u2019infection virale est survenue jusqu\u2019\u00e0 un an apr\u00e8s l\u2019arr\u00eat du traitement par le rituximab et a eu une issue fatale.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">En cas de r\u00e9activation de la tuberculose, un traitement conforme \u00e0 la pratique m\u00e9dicale courante et l\u2019arr\u00eat de l\u2019administration de TRUXIMA<sup>MD<\/sup> s\u2019imposent.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Des cas de pneumonie \u00e0 pneumocystis jirovecii (PPJ) ont \u00e9t\u00e9 signal\u00e9s, y compris chez des patients qui pr\u00e9sentaient plusieurs facteurs de risque. L\u2019emploi d\u2019une prophylaxie de la PPJ est \u00e0 envisager.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Effectuer une formule sanguine compl\u00e8te et une num\u00e9ration plaquettaire \u00e0 intervalles r\u00e9guliers pendant le traitement, et plus fr\u00e9quemment en pr\u00e9sence de cytop\u00e9nie.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Quatre cas d\u2019accident vasculaire c\u00e9r\u00e9bral ont \u00e9t\u00e9 signal\u00e9s chez des patients qui pr\u00e9sentaient des ant\u00e9c\u00e9dents de maladie cardiovasculaire ou des facteurs de risque cardiovasculaire.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">L\u2019emploi de TRUXIMA<sup>MD<\/sup> chez des patients atteints de PR qui n\u2019ont pas obtenu pr\u00e9alablement une r\u00e9ponse inad\u00e9quate \u00e0 un ou \u00e0 plusieurs anti-TNF n\u2019est pas recommand\u00e9.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-circle\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Il convient de conseiller aux femmes de ne pas allaiter pendant le traitement par TRUXIMA<sup>MD<\/sup> ni pendant 6 mois apr\u00e8s la derni\u00e8re dose, compte tenu du risque de effets ind\u00e9sirables graves chez les enfants nourris au sein.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f354db7 home-add-fontsize-para elementor-widget elementor-widget-text-editor\" data-id=\"f354db7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div><span style=\"text-decoration: underline;\"><b class=\"home-add-fontsize\">Pour plus de renseignements<\/b><\/span> :<\/div>\nConsultez la monographie de produit au <a class=\"anchor-tag-cls\" href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00084837.PDF\" target=\"_blank\" rel=\"noopener\">pdf.hres.ca\/dpd_pm\/00084837.PDF<\/a> pour obtenir des renseignements importants sur les effets ind\u00e9sirables, les interactions m\u00e9dicamenteuses, la posologie et l\u2019administration qui n\u2019ont pas \u00e9t\u00e9 abord\u00e9s dans le pr\u00e9sent document. Vous pouvez \u00e9galement vous procurer la monographie de produit en communiquant avec Teva Canada Innovation au 1-833-662-5644. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c209e13 hm_ul elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"c209e13\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-asterisk\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Pour obtenir la liste compl\u00e8te des indications dans le traitement du LNH, veuillez consulter la monographie de TRUXIMA<sup>MD<\/sup>.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-cross\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Les indications ont \u00e9t\u00e9 accord\u00e9es sur la base de la similarit\u00e9 entre TRUXIMA<sup>MD<\/sup> et le m\u00e9dicament biologique de r\u00e9f\u00e9rence Rituxan<sup>\u00ae<\/sup>.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">ANCA : <i>anti-neutrophilcytoplasmicantibody<\/i> (anticorps anticytoplasme des neutrophiles).<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f025531 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"f025531\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\"><b>R\u00e9f\u00e9rences :<\/b><\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\"><b>1 : <\/b>Monographie de TRUXIMA<sup>MD<\/sup>. Teva Canada Limit\u00e9e. 27 avril 2026. <b>2 : <\/b>Jennette JC, <i>et al<\/i>. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. <i>Arthritis Rheum<\/i>. 2013;65(1):1\u201311.<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Acc\u00e9dez aux plus r\u00e9centes ressources sur PrTRUXIMAMD et le programme de soutien aux patients Teva Support SolutionsMD Biosimilaires de conception.Biologique par essence. TRUXIMAMD en oncologie Lymphome non hodgkinien (LNH)1*\u2020 TRUXIMAMD (rituximab pour injection) est indiqu\u00e9 dans le traitement des patients atteints d\u2019un lymphome non hodgkinien de type B, CD20 positif, folliculaire, de stade III\/IV non [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-545","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Accueil - Truxima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/truximainfo.ca\/fr\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accueil - Truxima\" \/>\n<meta property=\"og:description\" content=\"Acc\u00e9dez aux plus r\u00e9centes ressources sur PrTRUXIMAMD et le programme de soutien aux patients Teva Support SolutionsMD Biosimilaires de conception.Biologique par essence. TRUXIMAMD en oncologie Lymphome non hodgkinien (LNH)1*\u2020 TRUXIMAMD (rituximab pour injection) est indiqu\u00e9 dans le traitement des patients atteints d\u2019un lymphome non hodgkinien de type B, CD20 positif, folliculaire, de stade III\/IV non [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/truximainfo.ca\/\" \/>\n<meta property=\"og:site_name\" content=\"Truxima\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-18T05:17:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"438\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/\",\"url\":\"https:\\\/\\\/truximainfo.ca\\\/\",\"name\":\"Accueil - Truxima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/truximainfo.ca\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Truxima_logo_FR.png\",\"datePublished\":\"2022-07-27T06:31:08+00:00\",\"dateModified\":\"2026-09-18T05:17:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/truximainfo.ca\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#primaryimage\",\"url\":\"https:\\\/\\\/truximainfo.ca\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Truxima_logo_FR.png\",\"contentUrl\":\"https:\\\/\\\/truximainfo.ca\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Truxima_logo_FR.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/truximainfo.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accueil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#website\",\"url\":\"https:\\\/\\\/truximainfo.ca\\\/\",\"name\":\"Truxima\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/truximainfo.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#organization\",\"name\":\"Truximainfo\",\"url\":\"https:\\\/\\\/truximainfo.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/truximainfo.ca\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Truxima_logo.png\",\"contentUrl\":\"https:\\\/\\\/truximainfo.ca\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/Truxima_logo.png\",\"width\":500,\"height\":188,\"caption\":\"Truximainfo\"},\"image\":{\"@id\":\"https:\\\/\\\/truximainfo.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accueil - Truxima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/truximainfo.ca\/fr\/","og_locale":"fr_FR","og_type":"article","og_title":"Accueil - Truxima","og_description":"Acc\u00e9dez aux plus r\u00e9centes ressources sur PrTRUXIMAMD et le programme de soutien aux patients Teva Support SolutionsMD Biosimilaires de conception.Biologique par essence. TRUXIMAMD en oncologie Lymphome non hodgkinien (LNH)1*\u2020 TRUXIMAMD (rituximab pour injection) est indiqu\u00e9 dans le traitement des patients atteints d\u2019un lymphome non hodgkinien de type B, CD20 positif, folliculaire, de stade III\/IV non [&hellip;]","og_url":"https:\/\/truximainfo.ca\/","og_site_name":"Truxima","article_modified_time":"2026-09-18T05:17:59+00:00","og_image":[{"width":1000,"height":438,"url":"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/truximainfo.ca\/","url":"https:\/\/truximainfo.ca\/","name":"Accueil - Truxima","isPartOf":{"@id":"https:\/\/truximainfo.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/truximainfo.ca\/#primaryimage"},"image":{"@id":"https:\/\/truximainfo.ca\/#primaryimage"},"thumbnailUrl":"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR.png","datePublished":"2022-07-27T06:31:08+00:00","dateModified":"2026-09-18T05:17:59+00:00","breadcrumb":{"@id":"https:\/\/truximainfo.ca\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/truximainfo.ca\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/truximainfo.ca\/#primaryimage","url":"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR.png","contentUrl":"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo_FR.png"},{"@type":"BreadcrumbList","@id":"https:\/\/truximainfo.ca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/truximainfo.ca\/"},{"@type":"ListItem","position":2,"name":"Accueil"}]},{"@type":"WebSite","@id":"https:\/\/truximainfo.ca\/#website","url":"https:\/\/truximainfo.ca\/","name":"Truxima","description":"","publisher":{"@id":"https:\/\/truximainfo.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/truximainfo.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/truximainfo.ca\/#organization","name":"Truximainfo","url":"https:\/\/truximainfo.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/truximainfo.ca\/#\/schema\/logo\/image\/","url":"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo.png","contentUrl":"https:\/\/truximainfo.ca\/wp-content\/uploads\/2022\/07\/Truxima_logo.png","width":500,"height":188,"caption":"Truximainfo"},"image":{"@id":"https:\/\/truximainfo.ca\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/truximainfo.ca\/fr\/wp-json\/wp\/v2\/pages\/545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/truximainfo.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/truximainfo.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/truximainfo.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/truximainfo.ca\/fr\/wp-json\/wp\/v2\/comments?post=545"}],"version-history":[{"count":180,"href":"https:\/\/truximainfo.ca\/fr\/wp-json\/wp\/v2\/pages\/545\/revisions"}],"predecessor-version":[{"id":3208,"href":"https:\/\/truximainfo.ca\/fr\/wp-json\/wp\/v2\/pages\/545\/revisions\/3208"}],"wp:attachment":[{"href":"https:\/\/truximainfo.ca\/fr\/wp-json\/wp\/v2\/media?parent=545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}